Polarean Imaging Announces Reimbursement-Code Pricing for MRI Technology Xenoview

Polarean Imaging, a leading medical imaging technology company, has revealed that the reimbursement-code price range for its innovative MRI technology Xenoview will be set at $1,201 to $1,300. This price range is in line with the company’s expectations and is a significant milestone in the commercialization of their product.

The newly established reimbursement code by the U.S. Centers for Medicare & Medicaid Services allows healthcare providers to bill for magnetic resonance imaging (MRI) procedures. This development has generated excitement in the market, leading to a recent surge in Polarean Imaging’s share prices.

Chief Executive Christopher von Jako expressed his satisfaction with the outcome, stating, “We’ve been working diligently with the U.S. Centers for Medicare & Medicaid Services and are pleased with this news, as it aligns perfectly with our original pricing reimbursement expectations.”

It is important to note that while the establishment of the reimbursement code is a positive step forward, it does not guarantee coverage or payment. Nonetheless, it serves as a crucial commercialization achievement for Polarean Imaging.

Overall, this announcement represents a significant development for Polarean Imaging and positions Xenoview as a valuable addition to the healthcare industry’s arsenal of imaging technologies.